Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the shares. BridgeBio recently announced its European partner Bayer (BAYRY) was granted a marketing authorization for transthyretin stabilizer acoramidis by the European Commission, which will treat adults with wild-type or variant transthyretin amyloidosis with cardiomyopathy, the analyst tells investors. The firm anticipates the EU launch of acoramidis in 1H25 will build on the momentum following its launch in the US.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces EC marketing authorization for BETONTTRA
- Bayer sees new drugs boosting return to growth in 2027, WSJ reports
- BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress
- JPMorgan ‘very encouraged’ by initial Attruby metrics presented by BridgeBio
- BridgeBio announces commercial progress, pipeline updates